Biofidelity Ltd., the largest cancer diagnostics firm, at this time announced that it has been granted a major patent within the US to defend its underlying expertise. The grant of US Patent US20200354786 reaffirms the innovation and invention of its expertise, designed to break the limits for screening, monitoring and treatment of most cancers through ultra-sensitive detection of tumor markers appropriate in treatment regimens has gone. .
It combines quick, easy-to-understand results with affordability, enabling oncologists to accurately select earlier, monitor resistance, and monitor disease recurrence. Biofidelity expects to launch its first product for detection of non-small cell lung most cancers, Identi-Lung, later this 12 months.
Dr Barnaby Balmforth, Chief Government Officer at Biofidelity, commented: “The grant of this major patent within the US is another significant step forward in our efforts to reevaluate our efforts to confirm that every person with cancer receives the appropriate medication at the appropriate time.”
Another important step in objective.. We are working hard to build a complete portfolio of IP to protect our expertise, objectives and merchandise in order to allow any laboratory to supply leading quality precision cancer diagnostics So to receive.”
Biofidelity, a private firm based in Cambridge, UK in 2019, is revolutionizing access to best-in-class most cancer diagnostics, breaking down boundaries for screening, monitoring and treatment for all cancer sufferers.
Its disruptive diagnostic expertise platform will provide oncologists with clinically actionable knowledge, based primarily on the hyper-sensitive identification of appropriate markers across most cancer treatment points, allowing them to prescribe the most appropriate cancer drug at an appropriate time. can.
It is designed to combine quick and easy-to-interpret results with affordability and easy adoption on current laboratory infrastructure, enabling many additional laboratories to supply most cancer diagnoses of prime quality. Biofidelity is initially specializing in the prognosis of most non-small cell lung and colorectal cancers, with the potential to detect resistance to treatment and disease recurrence in a broad range of cancers and medium to long-term objectives.